On Nov 21, major Wall Street analysts update their ratings for $Sage Therapeutics (SAGE.US)$, with price targets ranging from $4 to $14.
BofA Securities analyst Tazeen Ahmad maintains with a sell rating, and sets the target price at $4.
TD Cowen analyst Ritu Baral maintains with a hold rating, and adjusts the target price from $10 to $9.
Needham analyst Ami Fadia maintains with a hold rating.
Truist Financial analyst Joon Lee maintains with a hold rating.
H.C. Wainwright analyst Douglas Tsao maintains with a hold rating, and maintains the target price at $14.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Following the announcement that the phase 2 DIMENSION trial evaluating dalzanemdor in cognitive impairment associated with Huntington's disease did not meet the primary endpoint, there's a revised perspective on Sage Therapeutics. The evaluation resulted in a $75M reduction in pipeline value. It's noted that despite the trial results, the company has emphasized other early-stage assets, indicating that extensive clinical validation is imperative before additional value can be ascribed to these pipeline projects.
Here are the latest investment ratings and price targets for $Sage Therapeutics (SAGE.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
